Clinical Trial of Pulmonary Cryptococcosis in China
MCTOPCIC
Multi-center Clinical Trial of Pulmonary Cryptococcosis in China
1 other identifier
observational
260
0 countries
N/A
Brief Summary
The purpose of the study:1.Improve the understanding of the risk factors of pulmonary cryptococcosis;2.Improve the awareness of pulmonary cryptococcosis clinical and imaging manifestations;3.Grasp pulmonary cryptococcosis patients of clinical and imaging manifestations in different conditions;4.Learn about antibacterial activity of antifungal drugs for cryptococcosis in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2014
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
December 28, 2014
CompletedFirst Posted
Study publicly available on registry
July 21, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedJuly 21, 2015
July 1, 2015
2 years
December 28, 2014
July 17, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
differences in clinical manifestations of pulmonary cryptococcosis
Methods including laboratory examination(routine blood test),imaging examination(chest CT),scoring system(APACHE II score)
30 days
Secondary Outcomes (1)
treatment of pulmonary cryptococcosis
30 days
Eligibility Criteria
1. Improve the understanding of the risk factors of pulmonary cryptococcosis. 2. Improve the awareness of pulmonary cryptococcosis clinical and imaging manifestations. 3. Grasp pulmonary cryptococcosis patients of clinical and imaging manifestations in different conditions. 4. Learn about antibacterial activity of antifungal drugs for cryptococcosis in China.
You may qualify if:
- Patients possess clinical or imaging manifestations of pulmonary infections,with any of the results(by one of following conditions) by microbiological examination or histopathologic examination
- Cryptococcal capsular polysaccharide antigen of blood or pleural effusion is positive
- Cryptococcus（fungus culture) is discovered by lower respiratory tract specimens
- Cryptococcus（pleural effusions culture) is discovered by pleural effusions collected under sterile condition
- Cryptococcus（pus culture) is discovered by pus smear out of pulmonary infections in disseminated infection patients
- Cryptococcus（blood culture) is discovered by microscopy of specimens of blood smear
- Cryptococcus is discovered by culturing of the pathological tissue specimens in aseptic condition
- Cryptococcal capsular budding yeast with inflammatory reaction is discovered by histopathological examination,cell pathology examination or microscopic examination in aseptic condition
You may not qualify if:
- Patients suffer from acquired immune deficiency syndrome
- Patients or their legal guardians request to withdraw the clinical research
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zhixin Lianglead
- Chinese PLA General Hospitalcollaborator
- Beijing Chao Yang Hospitalcollaborator
- Ministry of Health, Chinacollaborator
- Peking University Third Hospitalcollaborator
- Tianjin Medical University General Hospitalcollaborator
- First Hospital of China Medical Universitycollaborator
- Shengjing Hospitalcollaborator
- Second Hospital of Jilin Universitycollaborator
- Shandong Provincial Hospitalcollaborator
- Huadong Hospitalcollaborator
- Nanjing PLA General Hospitalcollaborator
- Fuzhou General Hospitalcollaborator
- Guangzhou Institute of Respiratory Diseasecollaborator
- Wuhan TongJi Hospitalcollaborator
- Xi'an Jiaotong Universitycollaborator
- Guizhou Provincial People's Hospitalcollaborator
- Shenyang Military General Hospitalcollaborator
- The Second Hospital of Hebei Medical Universitycollaborator
- Xiangya Hospital of Central South Universitycollaborator
- Fujian Provincial Hospitalcollaborator
- Fuzhou Pulmonary Hospital of Fujiancollaborator
- Southwest Hospital, Chinacollaborator
- First Affiliated Hospital of Zhejiang Universitycollaborator
- Wenzhou Medical Universitycollaborator
- Shanghai Zhongshan Hospitalcollaborator
- The First Affiliated Hospital of Nanchang Universitycollaborator
- Longyan City First Hospitalcollaborator
Biospecimen
sputum,whole blood,pleural effusion,lung tissue,cerebrospinal fluid,fungus(smear examination,culture and identification,antigen detection,drug sensitive test)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Zhixin Liang, Doctor
Chinese PLA General Hospital
- PRINCIPAL INVESTIGATOR
Zhen Wang
Beijing Chao Yang Hospital
- PRINCIPAL INVESTIGATOR
Yanming Li
Ministry of Health, China
- PRINCIPAL INVESTIGATOR
Lina Sun
Peking University Third Hospital
- PRINCIPAL INVESTIGATOR
Jie Cao
Tianjin Medical University General Hospital
- PRINCIPAL INVESTIGATOR
Yunzhuo Chu
First Hospital of China Medical University
- PRINCIPAL INVESTIGATOR
Zhijie Zhang
Shengjing Hospital
- PRINCIPAL INVESTIGATOR
Yufen Jin
Second Hospital of Jilin University
- PRINCIPAL INVESTIGATOR
Xiaobin Ma
Shandong Provincial Hospital
- PRINCIPAL INVESTIGATOR
Yanping Zhu
Huadong Hospital
- PRINCIPAL INVESTIGATOR
Xin Su
Nanjing PLA General Hospital
- PRINCIPAL INVESTIGATOR
Guoxiang Lai
Fuzhou General Hospital
- PRINCIPAL INVESTIGATOR
Feng Ye
Guangzhou Institute of Respiratory Disease
- PRINCIPAL INVESTIGATOR
Shengdao Xiong
Wuhan TongJi Hospital
- PRINCIPAL INVESTIGATOR
Lan Yang
Xi'an Jiaotong University
- PRINCIPAL INVESTIGATOR
Hong Yu
Guizhou Provincial People's Hospital
- PRINCIPAL INVESTIGATOR
wencheng Xue
Shenyang Military General Hospital
- PRINCIPAL INVESTIGATOR
Yadong Yuan
The Second Hospital of Hebei Medical University
- PRINCIPAL INVESTIGATOR
Chengping Hu
Xiangya Hospital of Central South University
- PRINCIPAL INVESTIGATOR
Baosong Xie
Fujian Provincial Hospital
- PRINCIPAL INVESTIGATOR
Xiaohong Chen
Fuzhou Pulmonary Hospital of Fujian
- PRINCIPAL INVESTIGATOR
Xiangdong Zhou
Southwest Hospital, China
- PRINCIPAL INVESTIGATOR
Wenjiang Ma
First Affiliated Hospital of Zhejiang University
- PRINCIPAL INVESTIGATOR
Yuping Li
Wenzhou Medical University
- PRINCIPAL INVESTIGATOR
Hongni Jiang
Shanghai Zhongshan Hospital
- PRINCIPAL INVESTIGATOR
Wei Bai
The First Affiliated Hospital of Nanchang University
- PRINCIPAL INVESTIGATOR
Sucheng Zhong
Longyan City First Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Month
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Chinese Medical Association of respiratory diseases
Study Record Dates
First Submitted
December 28, 2014
First Posted
July 21, 2015
Study Start
December 1, 2014
Primary Completion
December 1, 2016
Study Completion
December 1, 2017
Last Updated
July 21, 2015
Record last verified: 2015-07